Michael Grundman - Concepedia

Author

Michael Grundman

Also Known As

>Michael Grundman, Anthony Gamst, Elaine Peskind, Frederick A. Schmitt, Grundman, M., M GRUNDMAN, M Grundman, M J Grundman, M Lu, M. Grundman

188

Publications

24.7K

Citations

H-Index

110

Concepts

All Affiliations

University of California San Diego University College London Pfizer (United States)Janssen (United States)Harvard University

About

Michael Grundman is an author at University of California San Diego specializing in medicine, neurology, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	32	5.9K
2	Health Sciences	10	10	1.7K
3	Education	1	1	23
4	Engineering	1	1	54
5	Nursing	1	1	44

Michael Grundman

Publications

21K

Citations

H-Index

Page 1

	Year	Citations
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease Mary Sano, Christopher Ernesto, Ronald G. Thomas, New England Journal of Medicine	1997	2.4K
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease Stephen Salloway, Reisa A. Sperling, Nick C. Fox, New England Journal of Medicine	2014	1.9K
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment Ronald Petersen, Ronald G. Thomas, Michael Grundman, New England Journal of Medicine	2005	1.8K
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease Douglas Galasko, David A. Bennett, Mary Sano, Alzheimer Disease & Associated Disorders AgingAlzheimerʼs DiseaseAd PatientsAlzheimer's DiseaseClinical Trials	1997	1.2K
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Ruth A. Mulnard, Carl W. Cotman, Claudia H. Kawas, PubMed	2000	985
Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials Michael Grundman Archives of Neurology	2004	965
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Paul Aisen, Kimberly Schafer, Michael Grundman, PubMed	2003	959
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Juha O. Rinne, David J. Brooks, Martin N. Rossor, The Lancet Neurology Neurodegenerative DiseasesAscending-dose StudyAlzheimer's Disease11C-pib Pet AssessmentBiomarkers	2010	694
Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs Richard C. Mohs, David S. Knopman, Ronald C. Petersen, Alzheimer Disease & Associated Disorders Antidementia DrugsNeuropsychologyPsychotropic MedicationPsychopharmacologyCognition	1997	676
Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease Joseph L. Price, Daniel W. McKeel, Virginia Buckles, Neurobiology of Aging Alzheimer's DiseaseAgingDementiaVascular DementiaNeuroscience	2009	648

Page 1